Overview

Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease

Status:
Not yet recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety and efficacy of Selinexor and Dexamethasone and see what effects it has on AL amyloidosis.
Phase:
Early Phase 1
Details
Lead Sponsor:
Weill Medical College of Cornell University
Collaborator:
Karyopharm Therapeutics Inc
Treatments:
Dexamethasone